hENT1 Predicts Benefit from Gemcitabine in Pancreatic Cancer but Only with Low CDA mRNA



Aughton, Karen ORCID: 0000-0002-5184-5789, Elander, Nils O, Evans, Anthony ORCID: 0000-0001-8547-1730, Jackson, Richard, Campbell, Fiona, Costello, Eithne, Halloran, Christopher M ORCID: 0000-0002-5471-4178, Mackey, John R, Scarfe, Andrew G, Valle, Juan W
et al (show 16 more authors) (2021) hENT1 Predicts Benefit from Gemcitabine in Pancreatic Cancer but Only with Low CDA mRNA. CANCERS, 13 (22).

[img] Text
cancers-13-05758.pdf - OA Published Version

Download (1MB) | Preview
Item Type: Article
Uncontrolled Keywords: 5-fluorouracil, gemcitabine, pyrimidine, biomarker, predictive marker, prognostic marker, chemotherapy
Divisions: Faculty of Health and Life Sciences
Faculty of Health and Life Sciences > Institute of Systems, Molecular and Integrative Biology
Depositing User: Symplectic Admin
Date Deposited: 18 Nov 2021 15:33
Last Modified: 25 Jan 2022 19:30
DOI: 10.3390/cancers13225758
Related URLs:
URI: https://livrepository.liverpool.ac.uk/id/eprint/3143425